162 related articles for article (PubMed ID: 32087501)
1. Parental history of diabetes mellitus has additive risk of metabolic syndrome in patients treated with clozapine.
Zeng Y; Chen S; Liu D; Hahn L; Xia X; Wen S; Han Z; Wu X
Asian J Psychiatr; 2020 Apr; 50():101939. PubMed ID: 32087501
[No Abstract] [Full Text] [Related]
2. Metabolic monitoring and management among clozapine users.
Tso G; Kumar P; Jayasooriya T; Kisely S; Siskind D
Australas Psychiatry; 2017 Feb; 25(1):48-52. PubMed ID: 27590080
[TBL] [Abstract][Full Text] [Related]
3. Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study.
Henderson DC; Nguyen DD; Copeland PM; Hayden DL; Borba CP; Louie PM; Freudenreich O; Evins AE; Cather C; Goff DC
J Clin Psychiatry; 2005 Sep; 66(9):1116-21. PubMed ID: 16187768
[TBL] [Abstract][Full Text] [Related]
4. The medical care of people with psychosis.
Lambert TJ
Med J Aust; 2009 Feb; 190(4):171-2. PubMed ID: 19220177
[No Abstract] [Full Text] [Related]
5. Metabolic syndrome in schizophrenia - who is more to blame: FGA polypharmacy or clozapine monotherapy?
Softic R; Sutovic A; Avdibegovic E; Osmanović E; Bećirović E; Hajdukov MM
Psychiatr Danub; 2015 Dec; 27(4):378-84. PubMed ID: 26609650
[TBL] [Abstract][Full Text] [Related]
6. Clozapine use and sedentary lifestyle as determinants of metabolic syndrome in outpatients with schizophrenia.
Eskelinen S; Sailas E; Joutsenniemi K; Holi M; Suvisaari J
Nord J Psychiatry; 2015 Jul; 69(5):339-45. PubMed ID: 25981178
[TBL] [Abstract][Full Text] [Related]
7. Clozaphobia: Is avoidance of clozapine in diabetes warranted?
Sreeraj VS; Dinakaran D; Nagendrappa S; Rao NP; Kesavan M; Varambally S; Venkatasubramanian G
Asian J Psychiatr; 2017 Aug; 28():142-145. PubMed ID: 28784368
[TBL] [Abstract][Full Text] [Related]
8. Metabolic predictors for mortality among patients treated with long-term clozapine - A longitudinal study.
Taub S; Hoshen M; Balicer R; Kamhi-Nesher S; Weizman A; Krivoy A
Eur Neuropsychopharmacol; 2020 Dec; 41():63-69. PubMed ID: 32981820
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of the metabolic syndrome among patients receiving clozapine.
Lamberti JS; Olson D; Crilly JF; Olivares T; Williams GC; Tu X; Tang W; Wiener K; Dvorin S; Dietz MB
Am J Psychiatry; 2006 Jul; 163(7):1273-6. PubMed ID: 16816234
[TBL] [Abstract][Full Text] [Related]
10. Complement 3 and metabolic syndrome induced by clozapine: a cross-sectional study and retrospective cohort analysis.
Zhang C; Zhang Y; Cai J; Chen M; Song L
Pharmacogenomics J; 2017 Jan; 17(1):92-97. PubMed ID: 26503818
[TBL] [Abstract][Full Text] [Related]
11. Metabolic syndrome and cardiovascular risk between clozapine and non-clozapine antipsychotic users with schizophrenia.
Quek YF; See YM; Yee JY; Rekhi G; Ng BT; Tang C; Lee J
Asian J Psychiatr; 2022 Aug; 74():103192. PubMed ID: 35751958
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular disease in patients with schizophrenia.
Kritharides L; Chow V; Lambert TJ
Med J Aust; 2017 Feb; 206(2):91-95. PubMed ID: 28152356
[TBL] [Abstract][Full Text] [Related]
13. Metabolic syndrome in schizophrenia: a comparative study of antipsychotic-free/naïve and antipsychotic-treated patients from India.
Pallava A; Chadda RK; Sood M; Lakshmy R
Nord J Psychiatry; 2012 Jun; 66(3):215-21. PubMed ID: 22017264
[TBL] [Abstract][Full Text] [Related]
14. Schizophrenia, antipsychotics, and the metabolic syndrome: is there a silver lining?
Remington G
Am J Psychiatry; 2006 Jul; 163(7):1132-4. PubMed ID: 16816213
[No Abstract] [Full Text] [Related]
15. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis.
Henderson DC; Cagliero E; Copeland PM; Borba CP; Evins AE; Hayden D; Weber MT; Anderson EJ; Allison DB; Daley TB; Schoenfeld D; Goff DC
Arch Gen Psychiatry; 2005 Jan; 62(1):19-28. PubMed ID: 15630069
[TBL] [Abstract][Full Text] [Related]
16. Prevalence and associations of the metabolic syndrome among patients prescribed clozapine.
Ahmed M; Hussain I; O'Brien SM; Dineen B; Griffin D; McDonald C
Ir J Med Sci; 2008 Sep; 177(3):205-10. PubMed ID: 18461270
[TBL] [Abstract][Full Text] [Related]
17. Routine data linkage to identify and monitor diabetes in clozapine-treated patients with schizophrenia.
Pearsall R; Gareze J; Park J; Walker A; Langan-Martin J; McLean G; Connelly M; Mackay D; Smith DJ
Schizophr Res; 2016 Dec; 178(1-3):107-108. PubMed ID: 27614569
[No Abstract] [Full Text] [Related]
18. Diabetes mellitus among outpatients receiving clozapine: prevalence and clinical-demographic correlates.
Lamberti JS; Costea GO; Olson D; Crilly JF; Maharaj K; Tu X; Groman A; Dietz MB; Bushey MP; Olivares T; Wiener K
J Clin Psychiatry; 2005 Jul; 66(7):900-6. PubMed ID: 16013906
[TBL] [Abstract][Full Text] [Related]
19. Cardio-metabolic risk and its management in a cohort of clozapine-treated outpatients.
Lappin JM; Wijaya M; Watkins A; Morell R; Teasdale S; Lederman O; Rosenbaum S; Dick S; Ward P; Curtis J
Schizophr Res; 2018 Sep; 199():367-373. PubMed ID: 29486959
[TBL] [Abstract][Full Text] [Related]
20. The relationship between brain-derived neurotrophic factor and metabolic syndrome in patients with chronic schizophrenia: A systematic review.
Kalejahi P; Kheirouri S; Noorazar SG; Sanayei M
Neuropeptides; 2021 Jun; 87():102135. PubMed ID: 33812160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
